SAMANTREE-MEDICAL
14.5.2019 12:43:07 CEST | Business Wire | Press release
SamanTree Medical, committed to reducing the need for cancer surgery re-operation particularly in breast surgery, announced today the successful closing of its CHF 9.5 million Series A financing. Proceeds will be used to commercialize the patented Histolog™ system, notably the recently CE mark Histolog™ Scanner v2, for enabling precise tumor removal at first surgery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005476/en/
Panakès Partners, the Medtech European leading venture capital mixing strong corporate and investment expertise, has led this round, alongside the Sioux Tech Fund, the venture arm of Sioux Technologies, a company with expertise in high-tech manufacturing, software development and data analytics. Existing shareholders and new investors BOM Brabant Ventures and btov Partners were participating as well.
“The timing is impeccable with the recently awarded European project, we are combining the right supports for executing on our mission to bring the gold standard in the Operating Room” said CEO and Co-Founder Bastien Rachet. The European Innovation Council awarded SamanTree Medical with EUR 2.3 million grant in September 2018, via its H2020 SME’s Instrument Program.
More than 500,000 lumpectomies are performed annually in the USA and Europe alone and up to 25% require re-operation. Additional operation is a burden for the patient and it increases the stress relative to the treatment; it also results in annual costs of $2.7 billion. Surgeons face a difficult trade-off: maximize confidence in removal of the entire tumor and minimize removal of healthy tissue. The “Gold Standard” for margin assessment is histopathology microscopy – these laboratory results, however, aren’t available until days after surgery. Surgeons need faster support for margin assessment in the operating room, ideally in real-time and with accuracy comparable to this “Gold Standard”.
SamanTree’s Histolog™ is the only solution that enables a global mapping of a lumpectomy for full margin control with histology-grade confidence in few minutes before closing the incision. With this innovative and highly practical imaging modality, the clinician is one touch-on-the-screen away from visualizing cancerous cell on a surgical specimen immediately during surgery. Enhancing the decision-making process during the surgery, this solution carries the promise of a better patient care, by increasing the confidence in a complete tumor removal at first surgery.
About SamanTree Medical
SamanTree Medical, a spin-off
company from the Swiss Federal Institute of Technology (EPFL), develops
disruptive imaging modalities and data analytic solutions for improving
cancer treatment care. Founded in December 2014, SamanTree is
headquartered in Lausanne, Switzerland. www.samantree.com
About Panakès Partners
Panakès Partners is a Venture Capital
investor that finances medical companies, early stage startups and SMEs,
with extremely promising products and great ambition, in Europe and
Israel, improving both patient outcomes and healthcare economics.
Investments focus on the medical device, diagnostics and healthcare IT
fields. Panakès Partners is headquartered in Milan, Italy.
www.panakes.it
/ Contact: contact@panakes.it
About the Sioux Tech Fund
The investment fund of high-tech
company Sioux Technologies, together with regional and European partners
(such as the Brabant Development Agency and the European Angel Fund),
invests in promising technical start-ups. This gives innovative ideas a
chance for faster development in terms of technological progress and
faster market introduction.
www.sioux.eu
/ Contact: info@sioux.eu
About BOM Brabant Ventures
BOM (the Brabant Development
Agency) works together with entrepreneurs to create a strong,
sustainable, and future-proof Brabant economy. BOM uses the Brabant
Ventures label to focus, using knowledge and capital, on the accelerated
and future-proof growth of ambitious Brabant startups and scaleups in
the high-tech systems and software, agri-food, life sciences & health,
maintenance, supply chain, and bio-based economy top industries.
www.bom.nl
/ Contact: info@bom.nl
SamanTree Medical has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No.823284.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005476/en/
Contact:
For more information regarding this press release, please contact: Florence Besnier, Executive Office Manager +41 21 625 09 40 Email: info@samantree.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
FIFA and Fanatics Expand Wide-Ranging Relationship to Include Historic Exclusive Collectibles Agreement (Trading Cards, Stickers and Trading Card Games)7.5.2026 13:00:00 CEST | Press release
Partnership includes FIFA tournaments and events from 2031Agreement encompasses both physical and digital collectibles, and for the first time brings the player jersey patch program to international footballPre-match press conferences for the FIFA World Cup Final to take place at Fanatics Fest on Friday, 17 July 2026 In a landmark agreement expanding their already successful wide-ranging commercial relationship, FIFA and Fanatics have signed a long-term, exclusive collectibles licensing deal that features trading cards, stickers, and trading card games. The agreement, which will begin in full in 2031, covers both physical and digital collectibles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507105628/en/ An example of the product innovations that will be brought to fans under this new partnership is the highly sought-after player jersey patch program, including debut patches, which will be inserted into football tradin
DEFINITIVE Trial Reaches Major Milestone: All Centres Approved and More Than 50% Recruitment Achieved7.5.2026 11:21:00 CEST | Press release
Poster presented at ESMO Breast Cancer 2026: Exploring health policy and real-world treatment strategies for early-stage HER2-positive breast cancer across Europe. The DEFINITIVE project, a landmark European Union-funded international phase III clinical trial evaluating the use of the HER2DX diagnostic assay to guide personalised treatment in early-stage HER2-positive breast cancer (BC), announces two major operational milestones at the ESMO Breast Cancer 2026 congress. Approvals have been obtained in the 7 participating countries, 33 clinicals sites are now open for patient recruitment. The trial has reached over 50% of its recruitment target, marking a pivotal moment on the path toward to transforming HER2-positive BC treatment. About the DEFINITIVE Project The DEFINITIVE project is a 5-year, prospective, open-label, randomised, two-arm phase III international clinical trial conducted across 44 centres in 7 European member states and associated countries. The trial aims to demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom